Convergen Closes $15 Million Financing to Advance Novel Protein Degradation Therapies for Neurodegenerative Diseases
Suzhou-based Convergen has secured $15 million in Seed+ financing to advance its next-generation targeted protein degradation platform and pipeline for neurodegenerative diseases, as the Chinese biotech seeks to translate its TRIM21-based approach for…